Membranes exert indirect negative control on phospholipase A2 in human placenta.
Phospholipase A2 (PLA2) activity of human term placenta is distributed about equally between cytosol and membranes. The latter activity was detached by treating membranes with EGTA, but this extraction also released inhibitory protein, which complicated the assay and has probably often led to underestimation of such PLA2. Varying the substrate concentration, we found that large amounts of liposome substrate relieve PLA2 suppression in the extract. This suggests substrate depletion by the inhibitory protein as the mechanism by which PLA2 enzymes are negatively controlled in placenta. Membrane-bound PLA2 was purified about 700-fold and appeared to be one enzyme species (PLA2-M). By contrast, cytosolic PLA2 activity could be fractionated into four separate fractions, one of which was further purified (PLA2-S1). As judged on the basis of a variety of biochemical properties, PLA2-M and PLA2-S1 seem to be identical enzyme forms. They are distinct from the class of pancreas/venom-type phospholipases A2.
Buhl
W J
WJ
Institut für Biologische Chemie, Universität Heidelberg, Federal Republic of Germany.
Zipfel
M
M
Garcia
M T
MT
Eisenlohr
L M
LM
Gehring
U
U
D003600:Cytosol / Q000201:enzymology; D004533:Egtazic Acid; D005260:Female; D006801:Humans; D008566:Membranes / Q000201:enzymology; D010741:Phospholipases A / Q000302:isolation & purification / Q000378:metabolism*; D054467:Phospholipases A2; D010920:Placenta / Q000201:enzymology*; D011247:Pregnancy; D013379:Substrate Specificity
D004533:Egtazic Acid; D010741:Phospholipases A; D054467:Phospholipases A2